GM-CSF-TAT-CEA recombinant protein as well as method and application thereof

A GM-CSF-TAT-CEA and recombinant protein technology, applied in the field of GM-CSF-TAT-CEA recombinant protein, can solve the problems of premature apoptosis and low specificity of DC cell antigens, and achieve easy preparation and long life cycle Improvement, the effect of antigen specificity improvement

Active Publication Date: 2014-05-14
SHANGHAI CLAISON BIOTECH
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In view of the shortcomings of DC cells induced by conventional methods at this stage, such as low antigen specificity and premature apoptosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • GM-CSF-TAT-CEA recombinant protein as well as method and application thereof
  • GM-CSF-TAT-CEA recombinant protein as well as method and application thereof
  • GM-CSF-TAT-CEA recombinant protein as well as method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] In this example:

[0026] The human colon cancer Lovo cell line-specific antigen CEA was obtained from NCBI, and the serial number is CAE75559;

[0027] TAT transmembrane peptide was obtained from NCBI, the serial number is NP_057853,

[0028] Granulocyte colony-stimulating growth factor GM-CSF was obtained from NCBI with the serial number AAA52578.

[0029] The map of plasmid pET-15b is as follows Figure 7 as shown,

[0030] a. Using gene synthesis technology, the gene sequence of human colon cancer Lovo cell line specific antigen CEA, the gene sequence of TAT transmembrane peptide and the gene sequence of GM-CSF were respectively synthesized. Among them, enzyme cleavage sites Nde I and Nco I are added to both ends of the gene sequence of granulocyte colony-stimulating growth factor GM-CSF; enzyme cleavage sites Xho I and Nde I are added to both ends of the gene sequence of TAT transmembrane peptide; Add restriction sites BamH I and Xho I at both ends; use the gen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a recombinant protein as well as a method and application thereof, and specifically relates to a GM-CSF-TAT-CEA recombinant protein as well as a method and application thereof, wherein the amino acid sequence table of the GM-CSF-TAT-CEA recombinant protein is as shown in SEQ ID NO: 1; for preparation, a recombinant plasmid is constructed by cloning GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor), TAT (Thrombin-Anti-Thrombin complexes) and CEA (Carcino Embryonie Antigen) to the cloning sites of a plasmid pET-15b through enzyme digestion, escherichia coli BL21 cells are transformed by the recombinant plasmid to express the recombinant protein, and finally, purification and collection of the transformant of the recombinant protein are carried out; the recombinant protein can be applied to tumor treating drugs. A fusion protein which has specificity and is capable of delaying the service life of DCs (Dendritic Cells) is prepared by combining tumor specific antigens, transducin and a key reagent GM-CSF for induction in vitro of the DCs, and the prolonging of the survival time of the DCs and the activation of specific immune response are guaranteed; extra addition of the GM-CSF in conventional DC culture is avoided, the defect of insufficient GM-CSF in the culture period is overcome and a cytotoxic effect also can be promoted by co-expression of the GM-CSF; besides, a new basis is provided for clinical treatment of tumors.

Description

[technical field] [0001] The invention relates to a recombinant protein and its method and application, in particular to a GM-CSF-TAT-CEA recombinant protein and its method and application. [Background technique] [0002] One of the fundamental reasons for the occurrence and development of tumors is that the body's immune system cannot effectively control its growth. To correct this, so that the body's immune system can effectively generate immune rejection against tumor cells has been studied for nearly a hundred years. topic. Tumor vaccines are the main content of research in this area. Among many tumor vaccines, dendritic cells (dendritic cells, DC) tumor vaccines designed according to the important role of antigen-presenting cells in tumor immunity are currently the most popular research direction. . The body's immune response is first captured, processed and processed by antigen presenting cells (antigen presenting cells, APCs), and then presented to T, B lymphocytes,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/70A61K39/00A61P35/00
Inventor 叶永清张超苏国新
Owner SHANGHAI CLAISON BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap